| Literature DB >> 34988610 |
Sławomir Liberski1, Bartlomiej J Kaluzny2, Jarosław Kocięcki3.
Abstract
Methanol-induced optic neuropathy (Me-ION) is a serious condition that may result in long-term or irreversible visual impairment or even blindness secondary to damage and loss of function of the optic nerve and retina. Me-ION shows a tendency to occur as mass poisonings around the world with a clear predilection for poor societies in developing countries. The main mechanism underlying the molecular basis of Me-ION is the inhibition of the mitochondrial oxidative phosphorylation process through the binding of the toxic metabolite of methanol-formic acid-with the key enzyme of this process-cytochrome c oxidase. However, other mechanisms, including damage to the eye tissues by oxidative stress causing the intensification of the oxidative peroxidation process with the formation of cytotoxic compounds, as well as an increase in the synthesis of pro-inflammatory cytokines and influence on the expression of key proteins responsible for maintaining cell homeostasis, also play an important role in the pathogenesis of Me-ION. Histopathological changes in the eye tissues are mainly manifested as the degeneration of axons and glial cells of the optic nerve, often with accompanying damage of the retina that may involve all its layers. Despite the development of therapeutic approaches, persistent visual sequelae are seen in 30-40% of survivors. Thus, Me-ION continues to be an important problem for healthcare systems worldwide.Entities:
Keywords: Methanol; Methanol-induced optic neuropathy; Methyl alcohol; Ocular toxicology; Optic nerve; Toxic optic neuropathy
Mesh:
Substances:
Year: 2022 PMID: 34988610 PMCID: PMC8731680 DOI: 10.1007/s00204-021-03202-0
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 5.153
Fig. 1Metabolism of methanol and its metabolites in the human body. Abbreviations: 10-CHO-THF 10-formyltetrahydrofolate, ADH alcohol dehydrogenase, ALDH aldehyde dehydrogenase, ALDH1A1 aldehyde dehydrogenase 1 family, member 1, ALDH2 mitochondrial aldehyde dehydrogenase, CYP2E1 cytochrome P450 Family 2 Subfamily E Member 1, NAD nicotinamide adenine dinucleotide, NADH reduced form of nicotinamide adenine dinucleotide, NADPH nicotinamide adenine dinucleotide phosphate
Fig. 2Mechanisms responsible for the molecular background of structural and functional changes in eye tissues in the course of methanol intoxication. Abbreviations: 5-HT serotonin, 5-HT2A serotonin 2A receptor, 5-HT2C serotonin 2C receptor, Asp aspartame, ATP adenosine triphosphate, GSH glutathione, IL-1β interleukin 1β, NF-ĸβ nuclear factor-kappa B, MDA malondialdehyde, Me-ION methanol-induced optic neuropathy, MPO myeloperoxidase, OSI oxidative stress index, ROS reactive oxygen species, SOD superoxide dismutase, TAS total anti-oxidant status, TNF-α tumor necrosis factor-alpha, TOS total oxidant status.
Summary of studies that investigated the efficacy of erythropoietin (EPO) alone or in combination with glucocorticoids (GCs) in Me-ION patients
| References | Sample size (eyes, | Intervention | Effects of the treatment | Explanatory comment |
|---|---|---|---|---|
| Pakdel ( | 34 eyes (Study group: 20; Control group: 14) | Study (EPO) group: 20 000 IU of EPO in 100 mL 0.9% saline in 2 h for 3 days (i.v.) Control group: 100 mL 0.9% saline (i.v.) | BCVA improvement (≤ − 0.2 logMAR): 85% of the eyes in EPO group vs. 43% in placebo group [ FBCVA: EPO group 1.84 vs. 2.79 logMAR in the control group ( | Phase-2 CT Double blind, randomized Criteria of eligibility: -Confirmed Me-ION -BCVA < 20/30 - < 3 weeks since methanol intoxication Primary outcome: BCVA at 16 week follow-up period |
| Zamani et al. ( | 30 eyes (Study group: 20; Control group 10) | Study group: 10 000 IU of EPO twice a day for 3 days (s.c.) with 250 mg of MP four times per day for 3 days (p.o.) Control group: 250 mg of MP four times per day for 3 days (p.o.) | BCVA improvement (median (IQR) VA): Study group: 0.002 and 0.004 at discharge and follow-up, respectively ( Control group: 0.025 and 0.053 at discharge and follow-up, respectively ( FBCVA was significantly better in control group than in study group after follow-up period ( In the study group tendency to initial transient improvement in VA followed by further VA deterioration (with a mean 2 months period) has been noted No significant difference in the eye movement exam ( | Case–control study Criteria of eligibility: -Survivors with the presence of visual disturbances which were not improved after implementation of HD Follow-up period ranged from 9 months to 4.5 years 14 of 15 patients undergone HD, and received ethanol, folinic acid, as well as bicarbonate. One patient received ADH blocker and bicarbonate |
| Pakdel et al. ( | 32 eyes | 20 00 IU of EPO for 3 days (i.v.) | BCVA improvement: Median BCVA before treatment: light perception (3.90–0.60 logMAR) Median FBCVA (measured in the better-seeing eye): 1.00logMAR [(3.90–0.00 logMAR); Median FBCVA was significantly better in patients with VA of HM or better at admission ( No significant difference in FBCVA improvement depending on patient age or time between exposure to methanol and treatment with EPO in OD ( No significant correlation between FBCVA and PRNFLT in the OD and OS | Prospective, noncomparative interventional case series Mean follow-up period: 7.5 months ± 55.8 Mean time period between exposure to methanol and treatment with EPO: 9.1 ± 5.56 days In 15 patients EPO course was repeated Criteria of eligibility: -Acute vision loss after methanol intoxication -Patients after detoxification treatment - < 3 weeks since methanol intoxication -Lack of VA improvement in the three preceding days -Lack of systemic disease -Value of anion gap in the serum < 11 mEq/L before admission Exclusion criteria: -Elevated BP -Positive history of TEEs or seizure -Hb level > 16 gm/dL -Positive history of eye disease or the presence of abnormalities during ophthalmological examination at admission -Treatment of ON with EPO or GCs in the past -Positive history of head injury in the last months |
| Pakravan et al. ( | 44 eyes (Study group: 22; Control group 22) | Study group: 10 000 IU of EPO twice a day for 3 days + 500 mg of MP twice a day for 5 days with further 14 days of oral prednisolone 1 mg/kg/day Control group: 500 mg of MP twice a day for 5 days with further 14 days of oral prednisolone 1 mg/kg/day | BCVA improvement: EPO group: 2.93 ± 0.55 at presentation vs. 1.75 ± 1.16 logMAR ( Control group: 2.65 ± 0.68 vs. 2.19 ± 0.75 logMAR ( FBCVA was significantly better in EPO group compared to control group ( PRNFLT: EPO group: 131 ± 34 at presentation vs. 77 ± 26 after 3 months follow-up period Control group: 187 ± 24 at presentation vs. 53 ± 6 after 3 month follow-up period Final PRNFLT EPO group 77 ± 26 vs. 53 ± 6 in the control group ( FVFMD: EPO group 25.21 ± 6.83 vs. 23.25 ± 3.67 in the control group ( | Non-randomized interventional study Primary outcome: BCVA, PRNFLT and VFMD at 6 moths follow-up period Criteria of eligibility: - < 2 weeks since methanol intoxication Exclusion criteria: DM, uncontrolled HT, Hb level > 16 mg/dl |
10-CHO-THF 10-formyltetrahydrofolate, ADH alcohol dehydrogenase, ALDH aldehyde dehydrogenase, ALDH1A1 aldehyde dehydrogenase 1 family, member 1, ALDH2 mitochondrial aldehyde dehydrogenase, CYP2E1 cytochrome P450 Family 2 Subfamily E Member 1, NAD nicotinamide adenine dinucleotide, NADH reduced form of nicotinamide adenine dinucleotide, NADPH nicotinamide adenine dinucleotide phosphate